Ipsen is spreading its bets in a fast-growing and competitive area of cancer drug research, striking a deal for a novel Foreseen Biotechnology antibody drug conjugate (ADC) that’s on track for its ...
Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors. Under current NCCN guidelines as of mid-December 2025, ...
A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced/metastatic solid tumors. Association of genomic ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
Erika Rasure is globally-recognized as a leading consumer economics subject matter expert, researcher, and educator. She is a financial therapist and transformational coach, with a special interest in ...
Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results